SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,377 | -12.1% | 49,942 | -4.2% | 0.00% | -25.0% |
| Q2 2023 | $1,567 | -19.3% | 52,113 | -2.7% | 0.00% | -20.0% |
| Q1 2023 | $1,941 | -1.9% | 53,572 | -3.4% | 0.01% | 0.0% |
| Q4 2022 | $1,978 | -99.9% | 55,450 | +0.3% | 0.01% | 0.0% |
| Q3 2022 | $1,872,000 | +23.3% | 55,299 | +5.4% | 0.01% | +25.0% |
| Q2 2022 | $1,518,000 | +8.5% | 52,475 | +21.2% | 0.00% | +33.3% |
| Q1 2022 | $1,399,000 | +10.9% | 43,293 | +0.0% | 0.00% | +50.0% |
| Q4 2021 | $1,262,000 | +10.1% | 43,279 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $1,146,000 | -14.2% | 42,958 | -0.9% | 0.00% | -33.3% |
| Q2 2021 | $1,335,000 | +17.3% | 43,343 | -0.3% | 0.00% | 0.0% |
| Q1 2021 | $1,138,000 | +3.7% | 43,474 | -0.3% | 0.00% | 0.0% |
| Q4 2020 | $1,097,000 | +20.5% | 43,609 | -0.1% | 0.00% | +50.0% |
| Q3 2020 | $910,000 | -12.8% | 43,668 | -0.7% | 0.00% | -33.3% |
| Q2 2020 | $1,044,000 | +32.0% | 43,969 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $791,000 | -20.2% | 43,969 | +5.3% | 0.00% | 0.0% |
| Q4 2019 | $991,000 | -13.4% | 41,774 | +0.2% | 0.00% | -25.0% |
| Q3 2019 | $1,145,000 | -15.7% | 41,674 | +1.5% | 0.00% | 0.0% |
| Q2 2019 | $1,358,000 | -2.9% | 41,046 | +2.8% | 0.00% | 0.0% |
| Q1 2019 | $1,399,000 | +13.6% | 39,938 | +7.7% | 0.00% | 0.0% |
| Q4 2018 | $1,232,000 | -32.5% | 37,084 | +2.2% | 0.00% | -33.3% |
| Q3 2018 | $1,826,000 | -14.2% | 36,269 | +2.1% | 0.01% | -14.3% |
| Q2 2018 | $2,127,000 | +33.9% | 35,532 | +2.5% | 0.01% | +40.0% |
| Q1 2018 | $1,588,000 | +25.7% | 34,672 | +9.4% | 0.01% | +25.0% |
| Q4 2017 | $1,263,000 | +1.6% | 31,705 | +2.0% | 0.00% | 0.0% |
| Q3 2017 | $1,243,000 | -5.0% | 31,080 | +2.4% | 0.00% | -20.0% |
| Q2 2017 | $1,308,000 | +48.6% | 30,340 | +7.9% | 0.01% | +25.0% |
| Q1 2017 | $880,000 | +32.5% | 28,130 | +7.0% | 0.00% | +33.3% |
| Q4 2016 | $664,000 | +5.7% | 26,280 | +3.5% | 0.00% | 0.0% |
| Q3 2016 | $628,000 | +79.4% | 25,390 | +48.0% | 0.00% | +50.0% |
| Q2 2016 | $350,000 | +50.2% | 17,160 | +12.4% | 0.00% | +100.0% |
| Q1 2016 | $233,000 | +17.1% | 15,270 | +3.0% | 0.00% | 0.0% |
| Q4 2015 | $199,000 | – | 14,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |